HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

CCM

Concord Medical Services Holdings Limited (NYSE)

Healthcare — Medical Care Facilities

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, and helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.

None
$4.51
$-0.21 (-4.45%)
Sign in to add CCM to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$19.58M
P/E Ratio (TTM)-
Forward P/E-30.07
EPS (TTM)$-3.13
Dividend Yield-
Profit Margin-20.15%
Revenue Growth57.40%
ROE-21.88%
Debt/Equity196.47
Recommendation None
Analyst Target-
Analysts-
Indexes NYSE

Technical Indicators

RSI (14)48.2
Beta-0.98
SMA 20-
SMA 40-
52-Week High$10.77
52-Week Low$3.18
50-Day Avg$4.72
200-Day Avg$4.54
Avg Volume39.0K
Volume127.6K

Performance Analysis

NEUTRAL

CCM presents a mixed picture with both positive and negative indicators.

~ Trading at 18% of its 52-week range.
~ RSI at 48.2 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ Strong revenue growth of 57.4% year-over-year.
- Operating at a loss with -20.2% margin.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:02 UTC

Back to Screener Export Report